Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30743049 | 1.00 | TSHR (0.73) | TSHRRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL1808274 | 0.93 | TSHR (0.63) | TSHRRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL8830836 | 0.91 | TSHR (0.70) | TSHRRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL184025 | 0.87 | TSHR (0.70) | TSHRALDH1A1GAASMN1; SMN2CYP1A2 | |
| SCHEMBL29521706 | 0.87 | TSHR (0.70) | TSHRALDH1A1GAASMN1; SMN2CYP1A2 | |
| SCHEMBL2997461 | 0.86 | TSHR (0.77) | TSHRRAB9AALDH1A1GAAKDM4E | |
| Hydrochloric Acid SCHEMBL8590467 | 0.85 | TSHR (0.68) | TSHRALDH1A1GAASMN1; SMN2CYP1A2 | |
| SCHEMBL1356474 | 0.85 | MAPT (0.57) | TSHRRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL111732 | 0.84 | TSHR (1.00) | TSHRRAB9AALDH1A1GAAKDM4E | |
| SCHEMBL23467802 | 0.83 | TSHR (0.73) | TSHRRAB9AALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953926-B1 | POSITION-SPECIFIC ASYMMETRIC DEUTERIUM ENRICHED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | TEVA PHARMACEUTICALS INT GMBH (CH) | 2021-10-20 | — | — | EP | disclosed |
| US-20210094904-A1 | POSITION-SPECIFIC ASYMMETRIC DEUTERIUM ENRICHED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | TEVA PHARMACEUTICALS INT GMBH (CH) | 2021-04-01 | — | — | US | disclosed |
| US-20200163918-A1 | POSITION-SPECIFIC ASYMMETRIC DEUTERIUM ENRICHED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | TEVA PHARMACEUTICALS INT GMBH (CH) | 2020-05-28 | — | — | US | disclosed |
| US-20200121812-A1 | Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease | TEVA PHARMACEUTICALS INT GMBH (CH) | 2020-04-23 | — | — | US | disclosed |
| CN-110577475-A | Ambroxol derivative, and preparation method, pharmaceutical composition and application thereof | 北京华睿鼎信科技有限公司 | 2019-12-17 | — | — | CN | disclosed |
| US-20180116989-A1 | Position-Specific Asymmetric Deuterium Enriched Catecholamine Derivatives And Medicaments Comprising Said Compounds | TEVA PHARMACEUTICALS INT GMBH (CH) | 2018-05-03 | — | — | US | disclosed |
| US-20180116989-A1 | Position-Specific Asymmetric Deuterium Enriched Catecholamine Derivatives And Medicaments Comprising Said Compounds | TEVA PHARMACEUTICALS INT GMBH (CH) | 2018-05-03 | — | — | US | disclosed |
| US-9763904-B2 | Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763904-B2 | Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20170165381-A1 | Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease | TEVA PHARMACEUTICALS INT GMBH (CH) | 2017-06-15 | — | — | US | disclosed |
| US-6020368-A | MICROBIOCIDES | HINKS JEREMY DAVID (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| CN-1214039-A | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM PLC (GB) | 1999-04-14 | — | — | CN | disclosed |
| EP-0874809-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-04 | — | — | EP | disclosed |
| US-5661153-A | FOR TREATING ALLERGIES, ASTHMA, DERMATITIS, GRAFT REJECTIONS | JAPAN ENERGY CORPORATION (JP) | 1997-08-26 | — | — | US | disclosed |
| WO-1997025309-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-17 | — | — | WO | disclosed |
| EP-0700908-A1 | 1-Arylpyrimidine derivatives and pharmaceutical use thereof | JAPAN ENERGY CORPORATION (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5488160-A | LEUKOTRIENE B4 RECEPTOR ANTAGONIST AS ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-01-30 | — | — | US | disclosed |
| US-5451700-A | Leukotriene inhibitors | CIBA-GEIGY CORPORATION (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0061157-A1 | 2-Benzoylamino substituted benzylamine derivative and a process for preparation thereof | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094904-A1 | POSITION-SPECIFIC ASYMMETRIC DEUTERIUM ENRICHED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | COMT, CHRM1, ADRB3 | TSHR 1594/4885RAB9A 1932/4885ALDH1A1 2132/4885 |
| US-20200121812-A1 | Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease | COMT, PNMT, THOP1 | TSHR 3113/4885RAB9A 991/4885ALDH1A1 426/4885 |
| US-20170165381-A1 | Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease | COMT, PNMT, THOP1 | TSHR 3113/4885RAB9A 991/4885ALDH1A1 426/4885 |
| US-20200163918-A1 | POSITION-SPECIFIC ASYMMETRIC DEUTERIUM ENRICHED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | COMT, CHRM1, ADRB3 | TSHR 1594/4885RAB9A 1932/4885ALDH1A1 2132/4885 |
| US-20180116989-A1 | Position-Specific Asymmetric Deuterium Enriched Catecholamine Derivatives And Medicaments Comprising Said Compounds | COMT, CHRM1, ADRB3 | TSHR 1594/4885RAB9A 1932/4885ALDH1A1 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.